SG Americas Securities LLC Has $102,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

SG Americas Securities LLC increased its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 33.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 17,475 shares of the company’s stock after purchasing an additional 4,419 shares during the period. SG Americas Securities LLC’s holdings in Olema Pharmaceuticals were worth $102,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Point72 Asset Management L.P. increased its stake in Olema Pharmaceuticals by 14.8% during the third quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock valued at $44,027,000 after acquiring an additional 475,447 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Olema Pharmaceuticals by 168.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after acquiring an additional 207,565 shares during the period. Great Point Partners LLC increased its stake in Olema Pharmaceuticals by 25.5% during the third quarter. Great Point Partners LLC now owns 1,000,000 shares of the company’s stock valued at $11,940,000 after acquiring an additional 203,120 shares during the period. JPMorgan Chase & Co. increased its stake in Olema Pharmaceuticals by 658.7% during the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock valued at $2,162,000 after acquiring an additional 157,171 shares during the period. Finally, Wellington Management Group LLP increased its stake in Olema Pharmaceuticals by 10.8% during the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after acquiring an additional 97,428 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, December 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $28.75.

Insider Buying and Selling

In related news, CEO Sean Bohen sold 52,328 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $490,313.36. Following the sale, the chief executive officer now directly owns 298,836 shares in the company, valued at $2,800,093.32. This represents a 14.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David C. Myles sold 12,452 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.38, for a total value of $116,799.76. Following the sale, the insider now owns 611,947 shares in the company, valued at approximately $5,740,062.86. This trade represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 773,797 shares of company stock worth $5,414,609 in the last three months. Insiders own 19.40% of the company’s stock.

Olema Pharmaceuticals Trading Down 5.4 %

OLMA stock opened at $4.94 on Thursday. Olema Pharmaceuticals, Inc. has a 1-year low of $4.60 and a 1-year high of $16.77. The firm has a market cap of $283.05 million, a P/E ratio of -2.26 and a beta of 2.05. The business’s 50 day moving average is $6.23 and its 200-day moving average is $9.89.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.